Arbutus Biopharma Corporation

2.99-0.0400-1.32%Vol 1.21M1Y Perf 139.92%
Apr 20th, 2021 16:00 DELAYED
BID2.97 ASK3.05
Open3.05 Previous Close3.03
Pre-Market- After-Market2.97
 - -  -0.02 -0.67%
Target Price
6.25 
Analyst Rating
Moderate Buy 1.67
Potential %
109.03 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap288.04M 
Earnings Rating
Sell
Price Range Ratio 52W %
24.63 
Earnings Date
10th May 2021

Today's Price Range

2.953.07

52W Range

1.029.02

5 Year PE Ratio Range

-2.10-1.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-9.94%
1 Month
-18.08%
3 Months
-24.49%
6 Months
7.17%
1 Year
139.92%
3 Years
-45.14%
5 Years
-40.79%
10 Years
3.10%

TickerPriceChg.Chg.%
ABUS2.99-0.0400-1.32
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
13.10
13.40
-
-
-14.90
Leverage Ratio -1.80
ProfitabilityValueIndustryS&P 500US Markets
-586.70
-864.00
-835.30
-7 709.20
-
RevenueValueIndustryS&P 500US Markets
5.42M
0.06
-14.94
-5.31
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.21-0.23-9.52
Q03 2020-0.20-0.27-35.00
Q02 2020-0.23-0.25-8.70
Q01 2020-0.32-0.2521.88
Q04 2019-0.37-0.362.70
Q03 2019-0.11-0.33-200.00
Q02 2019-0.35-0.46-31.43
Q01 2019-0.31-0.47-51.61
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.22-4.76Negative
6/2021 QR-0.22-4.76Negative
12/2021 FY-0.802.44Positive
12/2022 FY-0.630.00-
Next Report Date10th May 2021
Estimated EPS Next Report-0.22
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume1.21M
Shares Outstanding96.34M
Trades Count6.17K
Dollar Volume13.25M
Avg. Volume2.41M
Avg. Weekly Volume1.33M
Avg. Monthly Volume1.22M
Avg. Quarterly Volume2.31M

Arbutus Biopharma Corporation (NASDAQ: ABUS) stock closed at 2.99 per share at the end of the most recent trading day (a -1.32% change compared to the prior day closing price) with a volume of 1.21M shares and market capitalization of 288.04M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 80 people. Arbutus Biopharma Corporation CEO is William H. Collier.

The one-year performance of Arbutus Biopharma Corporation stock is 139.92%, while year-to-date (YTD) performance is -15.77%. ABUS stock has a five-year performance of -40.79%. Its 52-week range is between 1.02 and 9.02, which gives ABUS stock a 52-week price range ratio of 24.63%

Arbutus Biopharma Corporation currently has a PE ratio of -3.10, a price-to-book (PB) ratio of 2.46, a price-to-sale (PS) ratio of 53.83, a price to cashflow ratio of 7 665.10, a PEG ratio of 2.32, a ROA of -60.22%, a ROC of -57.55% and a ROE of 128.91%. The company’s profit margin is -%, its EBITDA margin is -835.30%, and its revenue ttm is $5.42 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Arbutus Biopharma Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Arbutus Biopharma Corporation’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Arbutus Biopharma Corporation is Moderate Buy (1.67), with a target price of $6.25, which is +109.03% compared to the current price. The earnings rating for Arbutus Biopharma Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arbutus Biopharma Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arbutus Biopharma Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 13.32, ATR14 : 0.32, CCI20 : -154.02, Chaikin Money Flow : -0.28, MACD : -0.26, Money Flow Index : 36.64, ROC : -9.01, RSI : 41.39, STOCH (14,3) : 1.89, STOCH RSI : 0.00, UO : 40.23, Williams %R : -98.11), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arbutus Biopharma Corporation in the last 12-months were: Michael J. McElhaugh (Sold 60 000 shares of value $300 232 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
4 (66.67 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Summary RatingModerate Buy
1.67
Moderate Buy
2.00
Moderate Buy
2.00

Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

CEO: William H. Collier

Telephone: +1 267 469-0914

Address: 701 Veterans Circle, Warminster 18974, PA, US

Number of employees: 80

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

54%46%

Bearish Bullish

59%41%

News

Stocktwits